MannKind Corporation (MNKD) NASDAQ
2.77
-0.05(-1.77%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
2.77
-0.05(-1.77%)
Currency In USD
Address
30930 Russell Ranch Road
Danbury, CA 91362
United States of America (the)
Phone
818 661 5000
Website
Sector
Healthcare
Industry
Biotechnology
Employees
403
First IPO Date
July 28, 2004
| Name | Title | Pay | Year Born |
| Michael E. Castagna | Chief Executive Officer & Director | 1.56M | 1977 |
| Sanjay Singh | Executive Vice President of Technical Operations | 364,529 | 1966 |
| Rosabel Realica Alinaya | Vice President of Investor Relations & Treasury | 402,256 | 1961 |
| Stuart A. Tross | Executive Vice President of Human Resources | 739,453 | 1967 |
| Christopher Prentiss | Chief Financial Officer | 824,525 | 1975 |
| David Thomson | Executive VP, General Counsel & Secretary | 858,438 | 1967 |
| Ajay Ahuja | Chief Medical Officer | 0 | N/A |
| Kevin Kaiserman | Senior Vice President & Therapeutic Area Head of Endocrine Diseases | 0 | N/A |
| Dominic Marasco | President of Endocrine Business Unit | 0 | 1972 |
| John F. Bedard | Senior Vice President of Worldwide Regulatory Affairs | 0 | 1950 |
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes. It also promotes Thyquidity to adult and pediatric endocrinologists, and other healthcare providers for the treatment of hypothyroidism. The company has a license and collaboration agreement with United Therapeutics Corporation. It also has an agreement with NRx Pharmaceuticals to develop a dry powder formulation of ZYESAMI (aviptadil), a synthetic form of human vasoactive intestinal peptide to help protect cells against inflammatory conditions. MannKind Corporation was incorporated in 1991 and is headquartered in Westlake Village, California.